Aug 01, 2022 / 12:00PM GMT
Operator
Good morning and thank you for standing by. Welcome to the Gamida Cell BLA acceptance call.
(Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Julian Adams, Chief Executive Officer. Please go ahead.
Julian Adams - Gamida Cell Ltd. - CEO
Thank you, operator. Good morning, everyone, and thanks for joining us.
2022 has been a remarkable year of meaningful momentum across all functions at Gamida Cell. And today, we continue with that momentum with the announcement that the FDA has accepted our BLA for omidubicel with priority review. We have some forward-looking statements and cautionary notes, and you can consult our SEC filings for further information.
So let me introduce today's program. I will begin with an overview of the pipeline and some key important milestones. I'll turn the call over to Ronit Simantov, our Chief Medical and Chief Scientific Officer, who will discuss omidubicel's clinical data.
And then after that, we
Gamida Cell BLA Acceptance Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot